Company intelligence
Imagene AI
A Cross-Modality Intelligence Engine for Precision Medicine
About Imagene AI
Imagene AI delivers precision Oncology Intelligence through robust multimodal foundation models and proprietary real-world data, accelerating biomarker discovery, patient stratification, response prediction, and companion diagnostic development. From H&E-based molecular profiling to AI-IHC companion diagnostics, Imagene AI develops AI-powered pathology assays that translate biological insight into patient selection and diagnostic strategies. LungOI®, the first AI-based NSCLC multi-gene biomarker panel to receive a PLA code and CMS payment rate, was developed, validated, and deployed across multiple centers and laboratories globally. We collaborate with leading biopharma organizations to advance biomarker-driven programs from discovery through clinical development and deployment.
Verified activity
Signals from Imagene AI
3 published signals
People
Imagene AI's leadership team includes Dean Bitan, Jonathan Zalach, Shahar Porat, Emre Gültürk, Michael Hreczuck, Katharina von Loga, MD, Inbal Gazy, Brian Laffin, and Kimberly Collins.
Reported by Imagene AI
People
Imagene AI appointed Emre Gültürk as Chief Regulatory and Market Access Officer.
Reported by Imagene AI
Presence & Recognition
Imagene AI team is attending WCLC 2026 in Seoul to connect with colleagues across thoracic oncology, digital pathology, biomarker research, and drug development.
Reported by Imagene AI